MAPT and Alzheimer disease: We further assessed concordance with a dataset from the ACA, where CSF samples from Aβ+/tau + AD patients and non-AD controls were analyzed using tandem mass tag labeling, Exploris 480 with “field asymmetric ion mobility spectrometry, and DDA (14).